ProCE Banner Activity

E3A06: Phase II/III Study of Lenalidomide vs Observation in Asymptomatic, High-Risk Smoldering Multiple Myeloma

Slideset Download
Conference Coverage
Lenalidomide significantly decreased the risk of progression vs observation in patients with high-risk smoldering multiple myeloma.

Released: June 05, 2019

Expiration: June 03, 2020

No longer available for credit.

Share

Provided by

Provided by the USF Health
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Astellas Seattle Genetics

Bayer Healthcare Pharma

Blueprint Medicines

Celgene

Novartis Pharmaceuticals Corporation

Puma Biotechnology, Inc.

Taiho Oncology Inc

Tesaro